| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Call redemptions of marketable securities | 8,500 | 6,000 |
| Net cash provided by (used in) investing activities | 46,268 | 29,212 |
| Proceeds from public offering, net of underwriting discounts and commissions | 187,948 | - |
| Aggregate gross proceeds from underwritten public offering | 0 | - |
| Proceeds from exercise of stock options | 1,460 | 1,330 |
| Payments related to offering costs | 254 | 0 |
| Proceeds from the issuance of series c convertible preferred stock-Series CConvertible Preferred Stock | 0 | - |
| Preferred stock issuance costs | 0 | - |
| Net cash provided by financing activities | 189,154 | 1,330 |
| Net increase in cash and cash equivalents | 173,774 | -9,570 |
| Cash and cash equivalents at beginning of period | 49,351 | - |
| Cash and cash equivalents at end of period | 223,125 | - |
MBX Biosciences, Inc. (MBX)
MBX Biosciences, Inc. (MBX)